Rn. Jones et al., Evaluation of gemifloxacin (SB-265805, LB20304a): in vitro activity against over 6000 Gram-positive pathogens from diverse geographic areas, INT J ANT A, 15(3), 2000, pp. 227-230
Gemifloxacin (GEMI), formerly SE-265805 and LB20304, is a newer fluoroquino
lone with broad-spectrum activity against a wide variety of bacterial patho
gens. The present investigation extended earlier observations by sampling a
n additional 6790 Gram-positive organisms from more than 50 medical centres
on three continents. The reference broth microdilution method with recomme
nded medium supplements was used throughout. Selected results (number strai
ns tested; MIC90 for GEMI/trovafloxacin in mg/l; % less than or equal to 1
mg/l for GEMI/trovafloxacin) were: Staphylococcus aureus (3672; 2/2; 86/85)
, S. epidermidis (404; 1/ > 4; 92/71), Enterococcus faecalis (630; 4/ > 4;
76/66), E. faecium (216; > 4/ > 4; 15/11), Streptococcus pneumoniae (300; 0
.06/0.25; 100/97), beta-haemolytic streptococci (150; 0.06/0.25; 100/100) a
nd viridans group streptococci (150; 0.12/0.25; 99/97). Gemifloxacin appear
ed equal or superior to trovafloxacin in its overall Gram-positive spectrum
of activity pending a choice of the susceptible breakpoint concentration.
Continued in vitro, pharmacodynamic and clinical investigations of gemiflox
acin appear warranted. (C) 2000 Elsevier Science B.V. and International Soc
iety of Chemotherapy. All rights reserved.